We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mouse Model Reveals Link Between Omega-3 Fatty Acids and Prostate Cancer

By Biotechdaily staff writers
Posted on 02 Jul 2007
A recent study established a link between the level of omega-3 fatty acids in the diet and the development and progression of prostate cancer.

Investigators at Wake Forest University School of Medicine (Winston-Salem, NC, USA) worked with a line of mice that had been genetically engineered to lack the Pten tumor-suppressor gene, a gene that is missing in 60-70% of metastatic tumors in humans. More...
The engineered mice spontaneously developed prostate cancer and served as a model for the human disease.

The engineered mice and a control group possessing functional Pten were fed either a diet high in omega-3 (ratio of omega-6 to omega-3 was 1:1), a diet low in omega 3 (ratio omega-6 to omega-3 was 20:1), or a diet high in omega-6 (ratio of omega-6 to omega-3 was 40:1). Survival rates were compared and the animals' prostate glands were weighed to measure tumor progression.

Results published in the June 21, 2007, online edition of the Journal of Clinical Investigation revealed that over the course of the experiment, none of the control animals developed cancer while all the genetically engineered mice developed prostate tumors. By the end of the experiment, 60% of the animals on the high omega-3 diet had survived, 10% on the low omega-3 diet were alive, but none of the animals on the high omega-6 diet had survived.

When the enzyme omega-3 desaturase, which converts omega-6 to omega-3 fatty acids, was introduced into the Pten-knockout mice, tumor growth was reduced similarly to the omega-3 diet.

"This suggests that if you have good genes, it may not matter too much what you eat,” said senior author Dr. Yong Q. Chen, professor of cancer biology at Wake Forest University School of Medicine, "but if you have a gene that makes you susceptible to prostate cancer, your diet can tip the balance. Our data demonstrate the importance of gene-diet interactions, and that genetic cancer risk can be modified favorably by omega-3. This study clearly shows that diet can tip the balance toward a good or a bad outcome. It is possible that a change in diet could mean the difference between dying from the disease and surviving with it.”


Related Links:
Wake Forest University School of Medicine

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.